£540m investment at GSK – Stevenage to be the new HQ for Galvani Bioelectronics

Further investment by GSK into Hertfordshire

GSK announced today that they are entering a joint venture with Verily Life Sciences (owned by Alphabet, Googles holding company). The new organisation will be based at GSK’s main research centre in Stevenage, Hertfordshire. There will also be a second facility at the Verily site in California.

The investment which will be made over a seven year period will support the new company’s research into the field of medical Bioelectronics. The objective is to develop miniaturised implants that can be inserted into a patient to alter the existing electrical signals which control the activity of organs to address inflammatory, metabolic and hormonal disorders such as arthritis, diabetes and asthma. A spokesperson for GSK said that the potential new treatments will take many years to develop and will not be ready for human trials soon, however the longer term benefits look very encouraging.


The fact that electrical signals are able to change the functioning of the body has long been understood; in fact the new company has been named after Luigi Aloisio Galvani who pioneered this research in the 18th century. It is only now that significant developments into areas of miniaturisation; low power management and data analytics that have made it feasible to progress this from pure research.